Results 311 to 320 of about 147,902 (326)
Some of the next articles are maybe not open access.
Photosensitizers for Photodynamic Therapy
Advanced Healthcare Materials, 2019AbstractAs an emerging clinical modality for cancer treatment, photodynamic therapy (PDT) takes advantage of the cytotoxic activity of reactive oxygen species (ROS) that are generated by light irradiating photosensitizers (PSs) in the presence of oxygen (O2).
Minhuan Lan +5 more
openaire +3 more sources
Innovative therapies: photodynamic therapy
Thoracic Surgery Clinics, 2004Photodynamic diagnosis could be a useful tool for improving the diagnostic yield of tumor biopsy, especially for mesothelioma tumors that are sclerotic and particularly hypocellular. For PDD, the use of low doses of a sensitizing drug, such as 5-ALA, must be investigated further. The initial results of 5-ALA-mediated PDD are promising. The role, if any,
Evelio Rodriguez +2 more
openaire +3 more sources
2007
La thérapie photodynamique est une nouvelle approche, basée sur l'action sélective par la lumière de médicaments, dits photosensibilisateurs. Ces molécules, non toxiques en absence d'une lumière de longueur d'onde appropriée, génèrent, après irradiation lumineuse et en présence d'oxygène, des espèces très réactives entraînant la destruction du tissu ...
Barberi-Heyob, Muriel +14 more
openaire +2 more sources
La thérapie photodynamique est une nouvelle approche, basée sur l'action sélective par la lumière de médicaments, dits photosensibilisateurs. Ces molécules, non toxiques en absence d'une lumière de longueur d'onde appropriée, génèrent, après irradiation lumineuse et en présence d'oxygène, des espèces très réactives entraînant la destruction du tissu ...
Barberi-Heyob, Muriel +14 more
openaire +2 more sources
Photodynamic therapy for cancer
Nature Reviews Cancer, 2003The therapeutic properties of light have been known for thousands of years, but it was only in the last century that photodynamic therapy (PDT) was developed. At present, PDT is being tested in the clinic for use in oncology--to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin.
Dennis E. J. G. J. Dolmans +2 more
openaire +3 more sources
Dermatology, 2007
<i>Background:</i> Photodynamic therapy (PDT) is increasingly used in the treatment of various skin diseases. The main adverse effect in PDT treatment is pain. Each lesion is generally treated twice, and clinical experience suggests that the 2nd treatment causes more pain than the 1st and thus becomes a therapy-limiting factor.
Henriette M.V. Brogaard +2 more
openaire +3 more sources
<i>Background:</i> Photodynamic therapy (PDT) is increasingly used in the treatment of various skin diseases. The main adverse effect in PDT treatment is pain. Each lesion is generally treated twice, and clinical experience suggests that the 2nd treatment causes more pain than the 1st and thus becomes a therapy-limiting factor.
Henriette M.V. Brogaard +2 more
openaire +3 more sources
Photodynamic therapy for mesothelioma
Current Treatment Options in Oncology, 2001Multiple trials of traditional cancer therapies for malignant pleural mesothelioma (including surgery, radiation therapy, and chemotherapy) have not convincingly demonstrated that any one treatment is superior to supportive care alone. Although there have been reports of long-term survivors who were treated with aggressive surgery combined with ...
Stephen M. Hahn +2 more
openaire +3 more sources
Intraperitoneal Photodynamic Therapy
2007Peritoneal carcinomatosis and sarcomatosis are generally incurable problems for which there are few good treatment options. Intraperitoneal PDT is potentially an ideal therapy for peritoneal carcinomatosis because of its relatively superficial treatment effect.
Eli Glatstein +2 more
openaire +3 more sources
Photodynamic Therapy for Cholangiocarcinoma
Seminars in Liver Disease, 2004The prognosis of perihilar cholangiocarcinoma (CC) is limited by tumor spread along the biliary tree leading to refractory obstructive cholestasis, cholangitis, and liver failure. Palliation with biliary endoprostheses yields median survival times between 4 and 6 months for nonresectable CC.
openaire +3 more sources